Literature DB >> 12753867

Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice.

H Zhou1, A Iida-Klein, S S Lu, M Ducayen-Knowles, L R Levine, D W Dempster, R Lindsay.   

Abstract

The mouse is being increasingly used to study the anabolic action of parathyroid hormone (PTH) on the skeleton. The efficacy of intermittent PTH treatment on bone varies widely among tested strains of mice with differences in peak bone mass and structure. We have therefore examined the responses of skeletal sites with high or low cancellous bone mass to PTH treatment in a single strain with genetically low bone mass. Mature C57BL/6 mice were ovariectomized (ovx) or sham operated and, after 4 weeks, treated with PTH(1-34) (40 microg/kg/day, 5 days/week sc) or vehicle for 3 or 7 weeks. Two doses of fluorescent labels were given to the animals 9 and 3 days before euthanasia. Histomorphometry was performed on sections of the proximal tibia, tibial diaphysis, and vertebral body. The results indicate that 4 to 11 weeks of ovx induced a approximately 44% loss of cancellous bone in the proximal tibia and a approximately 25% loss of cancellous bone in the vertebra with impaired trabecular architecture and high bone turnover. In the intact animals, PTH increased cancellous bone volume to a greater extent in the vertebral body than in the proximal tibia, a site with lower cancellous bone volume at the outset. In the ovx mice, PTH increased cancellous bone volume to a greater extent in the vertebral body, a site displaying moderate cancellous bone loss, than in the proximal tibia, a site with severe cancellous bone loss. Conversely, the treatment added a little cortical bone to the tibia, a highly loaded site, but did not significantly increase cortical width of the vertebral body, a less loaded site. We conclude that, for intermittent PTH treatment to be maximally effective, there must be an adequate number of trabeculae present at the beginning of treatment, regardless of estrogen status. Our results also support an interaction between PTH anabolic action and mechanical loading.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12753867     DOI: 10.1016/s8756-3282(03)00057-7

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  25 in total

1.  Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice.

Authors:  Manshan Xu; Shilpa Choudhary; Olga Voznesensky; Qi Gao; Douglas Adams; Vilmaris Diaz-Doran; Qian Wu; David Goltzman; Lawrence G Raisz; Carol C Pilbeam
Journal:  Bone       Date:  2010-05-13       Impact factor: 4.398

2.  CREM deficiency in mice alters the response of bone to intermittent parathyroid hormone treatment.

Authors:  Fei Liu; Sun-Kyeong Lee; Douglas J Adams; Gloria A Gronowicz; Barbara E Kream
Journal:  Bone       Date:  2007-02-01       Impact factor: 4.398

3.  Osteoporotic fracture and parathyroid hormone.

Authors:  Nabanita S Datta
Journal:  World J Orthop       Date:  2011-08-18

4.  Effects of different doses of ferutinin on bone formation/resorption in ovariectomized rats.

Authors:  Francesco Cavani; Marzia Ferretti; Gianluca Carnevale; Laura Bertoni; Manuela Zavatti; Carla Palumbo
Journal:  J Bone Miner Metab       Date:  2012-07-25       Impact factor: 2.626

5.  beta-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice.

Authors:  Mary L Bouxsein; Dominique D Pierroz; Vaida Glatt; Deborah S Goddard; Fanny Cavat; Renée Rizzoli; Serge L Ferrari
Journal:  J Bone Miner Res       Date:  2004-12-06       Impact factor: 6.741

6.  Pharmacokinetics and osteogenic potential of PEGylated NELL-1 in vivo after systemic administration.

Authors:  Jin Hee Kwak; Yulong Zhang; Juyoung Park; Eric Chen; Jia Shen; Chirag Chawan; Justine Tanjaya; Soonchul Lee; Xinli Zhang; Benjamin M Wu; Kang Ting; Chia Soo
Journal:  Biomaterials       Date:  2015-04-24       Impact factor: 12.479

7.  Constitutive protein kinase A activity in osteocytes and late osteoblasts produces an anabolic effect on bone.

Authors:  Richard S Kao; Marcia J Abbott; Alyssa Louie; Dylan O'Carroll; Weidar Lu; Robert Nissenson
Journal:  Bone       Date:  2013-04-10       Impact factor: 4.398

8.  Postmenopausal women treated with combination parathyroid hormone (1-84) and ibandronate demonstrate different microstructural changes at the radius vs. tibia: the PTH and Ibandronate Combination Study (PICS).

Authors:  A L Schafer; A J Burghardt; D E Sellmeyer; L Palermo; D M Shoback; S Majumdar; D M Black
Journal:  Osteoporos Int       Date:  2013-04-16       Impact factor: 4.507

9.  Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation.

Authors:  Ronald R Gomes; Patricia Buttke; Emmanuel M Paul; Robert A Sikes
Journal:  Clin Exp Metastasis       Date:  2009-05-07       Impact factor: 5.150

10.  Effects of PTH treatment on tibial bone of ovariectomized rats assessed by in vivo micro-CT.

Authors:  J E M Brouwers; B van Rietbergen; R Huiskes; K Ito
Journal:  Osteoporos Int       Date:  2009-03-05       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.